1. Home
  2. NVAX

as 05-20-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
-
.
-
-
%

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Founded: 1987 Country:
United States
United States
Employees: N/A City: GAITHERSBURG
Market Cap: 1.9B IPO Year: 1995
Target Price: $14.00 AVG Volume (30 days): 12.9M
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.13 EPS Growth: N/A
52 Week Low/High: $3.53 - $15.00 Next Earning Date: 05-10-2024
Revenue: $996,609,000 Revenue Growth: -26.66%
Revenue Growth (this year): -11.9% Revenue Growth (next year): 9.36%

Share on Social Networks:

Stock Insider Trading Activity of Novavax Inc. (NVAX)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Dubovsky Filip NVAX President, R&D May 14 '24 Sell $13.90 47,312 $657,636.80 38,953 SEC Form 4